NASDAQ:BCAB
BioAtla, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.bioatla.comipo date
Dec 16, 2020
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops ...Show More
Earnings
Earnings Release in 3 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus